STAT Plus: A compounder loses a battle with the FDA over using bulk substances

A federal judge ruled the Food and Drug Administration correctly prevented a company from using an ingredient to make a compounded version of a medicine that is widely used by hospitals, a notable victory for drug makers that have been battling compounding pharmacies.

At issue was a dispute over whether a compounded form of vasopressin, which is used to increase blood pressure in patients with vasodilatory shock, filled a legitimate clinical need and, therefore, should be allowed to remain available alongside a brand-name version. The FDA tracks clinical need as part of its oversight of compounders that make and distribute large quantities of medicines.

Continue to STAT Plus to read the full story…

Read Original Article: STAT Plus: A compounder loses a battle with the FDA over using bulk substances »